Evolving Treatments in Hepatocellular Carcinoma: Updates from ASCO GI 2024 - Episode 15

REGONEXT Study: Driving Second-line HCC Treatment Strategy

Dr Morse discusses key takeaways from the REGONEXT study presented at ASCO GI 2024.

EP. 1: Hepatocellular Carcinoma (HCC) Disease State Overview
EP. 2: Utilizing Interventional Radiology and Liver-directed Therapies
EP. 3: Determining Transarterial Chemoembolization (TACE) Candidacy for Patients with HCC
EP. 4: EMERALD-1 Study: Significance as Presented at ASCO GI 2024
EP. 5: EMERALD-1 Study: Outshining Negative Clinical Trials Based Upon TKI- and Liver-directed Therapies
EP. 6: IMBrave-050 Study Overview
EP. 7: Patient Profile 1: Advanced HCC Treated with Durvalumab and Tremelimumab
EP. 8: HIMALAYA Study in Advanced Stage HCC
EP. 9: Establishing Optimal HCC Treatment Strategy
EP. 10: IMBrave150 Study Overview
EP. 11: HCC Treatment Strategy Driven by Real-World Evidence
EP. 12: Combining Liver-directed and Systemic Therapies in HCC
EP. 13: Patient Profile 2: Patient Progression After Frontline HCC Therapy
EP. 14: CARES-310 Trial: Impressions and Clinical Impact on HCC Treatment Landscape
Now Viewing
EP. 15: REGONEXT Study: Driving Second-line HCC Treatment Strategy
EP. 16: Trajectory of Evolving HCC Treatment Landscape